4.6 Article

Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome

Journal

CRITICAL CARE MEDICINE
Volume 43, Issue 9, Pages 1790-1797

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0000000000001089

Keywords

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; acute lung injury; acute respiratory distress syndrome; cigarette smoking; tobacco

Funding

  1. National Institutes of Health (NIH) [HL090833, KL2RR024130, HL110969]
  2. NIH [T32 HL087738, P30 DA012393, CA78603, HL081332, HL103836, HL112656]
  3. Flight Attendant Medical Research Institute (Young Clinical Scientist Award)
  4. GlaxoSmithKline
  5. Cerus
  6. National Cancer Institute and Food and Drug Administration Center for Tobacco Products [1P50CA18890, 1P50CA180890]
  7. National Heart, Lung, and Blood Institute (NHLBI) [HL51856]
  8. NHLBI [1K23HL116800-01]
  9. NIH (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK] K23 Award) [DK088964-03]
  10. NIH NIDDK
  11. AstraZeneca
  12. Flight Attendant Medical Research Institute
  13. California Tobacco Related Disease Research Program
  14. Flight Attendants Medical Research Institute
  15. Flight Attendants Medical Research Institute (University of California San Francisco Bland Lane Center of Excellence in Secondhand Smoke)
  16. American Heart Association

Ask authors/readers for more resources

Objective: The association between cigarette smoke exposure and the acute respiratory distress syndrome in patients with the most common acute respiratory distress syndrome risk factors of sepsis, pneumonia, and aspiration has not been well studied. The goal of this study was to test the association between biomarker-confirmed cigarette smoking and acute respiratory distress syndrome in a diverse cohort. Design: Prospective cohort. Setting: Tertiary care center. Patients: Four hundred twenty-six critically ill patients with acute respiratory distress syndrome risk factors (excluding trauma and transfusion) Interventions: None. Measurements and Main Results: We obtained smoking histories and measured urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (a biomarker of cigarette smoke exposure) on urine samples obtained at the time of study enrollment. The association between cigarette smoke exposure and acute respiratory distress syndrome differed based on acute respiratory distress syndrome risk factor (p < 0.02 for interaction). In patients with nonpulmonary sepsis as the primary acute respiratory distress syndrome risk factor (n = 212), 39% of those with acute respiratory distress syndrome were current smokers by history compared with 22% of those without acute respiratory distress syndrome (odds ratio, 2.28; 95% CI, 1.24-4.19; p = 0.008). Likewise, cigarette smoke exposure as measured by urine 4-(methylnitrosamino)-1-(3-pyridyl)1-butanol was significantly associated with acute respiratory distress syndrome in this group. The increased risk of acute respiratory distress syndrome in nonpulmonary sepsis was restricted to patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels consistent with active smoking and was robust to adjustment for other acute respiratory distress syndrome predictors. Cigarette smoke exposure as measured by history or 4-(methylnitrosamino)1-(3-pyridyl)-1-butanol was not associated with acute respiratory distress syndrome in patients with other risk factors (e.g., pneumonia and aspiration). Conclusions: Cigarette smoking measured both by history and biomarker is associated with an increased risk of acute respiratory distress syndrome in patients with nonpulmonary sepsis. This finding has important implications for tobacco product regulation and for understanding the pathogenesis of acute respiratory distress syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available